Table IV.
Function and pathway | ID | Description | Count in gene set | False discovery rate |
---|---|---|---|---|
Biological process | GO: 0001501 | Skeletal system development | 20 | 2.03×10−20 |
(GO) | GO: 0009888 | Tissue development | 27 | 3.18×10−19 |
GO: 0001503 | Ossification | 16 | 2.27×10−18 | |
GO: 0071495 | Cellular response to endogenous stimulus | 21 | 4.40×10−18 | |
GO: 0071363 | Cellular response to growth factor stimulus | 17 | 5.39×10−18 | |
Molecular function | GO: 0046332 | Mothers against decapentaplegic homolog binding | 10 | 5.84×10−14 |
(GO) | GO: 0005515 | Protein binding | 32 | 4.67×10−13 |
GO: 0005160 | Transforming growth factor β receptor binding | 8 | 1.02×10−11 | |
GO: 0005126 | Cytokine receptor binding | 10 | 1.09×10−9 | |
GO: 0019838 | Growth factor binding | 8 | 1.58×10−9 | |
Cellular component | GO: 0005615 | Extracellular space | 20 | 2.99×10−13 |
(GO) | GO: 0044421 | Extracellular region part | 26 | 2.01×10−10 |
GO: 0005576 | Extracellular region | 27 | 3.32×10−10 | |
GO: 0031012 | Extracellular matrix | 12 | 3.32×10−10 | |
GO: 0005578 | Proteinaceous extracellular matrix | 11 | 1.35×10−9 | |
KEGG pathways | 4350 | Transforming growth factor-β signaling pathway | 13 | 1.50×10−20 |
5200 | Pathways in cancer | 17 | 2.04×10−19 | |
4390 | Hippo signaling pathway | 12 | 1.87×10−15 | |
5205 | Proteoglycans in cancer | 12 | 1.53×10−13 | |
4151 | Phosphoinositide 3-kinase-protein kinase B signaling pathway | 12 | 2.49×10−11 |
GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.